Tipranavir (Aptivus): Research
- Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir (September 15, 2010)
From National AIDS Treatment Advocacy Project
- New Data on Tipranavir Highlight the Agent's Benefits (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
- A Research Update on Tipranavir (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- A Thorough Look at Tipranavir Based on Studies Assessing Its Efficacy, Resistance and Safety (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
On TheBodyPRO.com
- Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance (August 17, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- Use of Tipranavir for Patients With Little Prior PI Experience (August 15, 2006)
In XVI International AIDS Conference
On TheBodyPRO.com
- Tipranavir Update at CROI 2006: RESIST Study Results, Drug Interactions and Therapeutic Drug Monitoring (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
On TheBodyPRO.com
- Ritonavir-Boosted Tipranavir Increases ALT and AST Levels in HIV/Hepatitis-Coinfected Patients (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
- Tipranavir Heralds New Era for Treatment-Experienced Patients, Recent Studies Attest (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Ritonavir-Boosted Tipranavir Update at CROI 2005 (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group
- News on Developing Drugs and Drug Interactions (September/October 2004)
Updates on tipranavir, GS 9005 and the interaction between ddI and tenofovir.
In GMHC Treatment Issues, from Gay Men's Health Crisis
On TheBodyPRO.com
- Tipranavir Reduces Concentrations of Other Protease Inhibitors (July 14, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Anti-HIV Therapy Update (July 2004)
A quick briefing on tipranavir, TMC-114, capravirine and D-D4FC.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
On TheBodyPRO.com
- Tipranavir Pharmacokinetics May Confine Its Use to Limited Rescue Role (June 2004)
In TAGline, from Treatment Action Group
On TheBodyPRO.com
- Drug Development News: Boehringer Ingelheim (May/June 2004)
An update on the protease inhibitor tipranavir and the NRTI alovudine, both for treatment-experienced patients.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Tipranavir/Ritonavir's Resistance Profile in Multiple-Protease-Inhibitor-Experienced Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
